modakafusp alfa + lenalidomide

modakafusp alfa + lenalidomide is a combination therapy consisting of modakafusp alfa, a novel immunocytokine fusion protein, and lenalidomide, an immunomodulatory agent. - **Modakafusp alfa** is a fusion protein designed to deliver attenuated human interferon alpha-2b directly to CD38-positive cells, including malignant plasma cells, by targeting the cell surface marker CD38. Its mechanism combines direct cytotoxicity to tumor cells with immune activation, resulting in anti-myeloma effects even in patients resistant to other anti-CD38 monoclonal antibodies. - **Lenalidomide** is a small molecule immunomodulatory drug that modulates the substrate specificity of the CRL4CRBN E3 ubiquitin ligase, leading to the ubiquitination and degradation of key transcription factors in myeloma cells, ultimately inhibiting proliferation and promoting apoptosis. This combination is under clinical investigation as a maintenance therapy following autologous stem cell transplantation (ASCT) and as a treatment for relapsed/refractory multiple myeloma, aiming to improve outcomes beyond what either agent achieves alone[1][3][5].